Primary Immune Deficiency (PID) - Epidemiology Forecast to 2028

Primary Immune Deficiency (PID) - Epidemiology Forecast to 2028

  • Pages: 50
  • Geography: Global
  • Delivery Timeline:
  • Publication: Jan, 2019
  • SKU: DIEI0187
  • Single User Price
    ()
    $3,250.00
  • Site User Price
    ()
    $6,500.00
  • Enterprise Price
    ()
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's Primary Immune Deficiency (PID)   - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Primary Immune Deficiency (PID)   epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. 

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2016-2028

Primary Immune Deficiency (PID) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Primary Immune Deficiency (PID)   in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Primary Immune Deficiency (PID)   outlook. It also includes the explanation of changing trends of epidemiology outlining the Primary Immune Deficiency (PID)   scenario.

Primary Immune Deficiency (PID) Epidemiology
Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Primary Immune Deficiency (PID)   thereby presenting the trends with detailed analysis, with the assumptions undertaken.
The data is presented in the form of graphs along with tables to effectively summarize the landscape.
Report Scope
• The report covers detailed overview of Primary Immune Deficiency (PID)   explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Primary Immune Deficiency (PID)   Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage 
• Total Cases in Primary Immune Deficiency (PID)  

Key assessments
• Patient Segmentation in Primary Immune Deficiency (PID)  
• Primary Immune Deficiency (PID)   Risk & Burden
• Factors driving growth in a specific Primary Immune Deficiency (PID)   patient population

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Table 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Table 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Table 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Table 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Table 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Table 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Table 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Figure 1: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Immune Deficiency (PID) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 9: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028) 
Figure 10: Diagnosed Cases of the Primary Immune Deficiency (PID) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 13: Sex- Specific Cases of the Primary Immune Deficiency (PID) in France (2016-2028) 
Figure 14: Diagnosed Cases of the Primary Immune Deficiency (PID) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 17: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028) 
Figure 18: Diagnosed Cases of the Primary Immune Deficiency (PID) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 21: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028) 
Figure 22: Diagnosed Cases of the Primary Immune Deficiency (PID) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 25: Sex- Specific Cases of the Primary Immune Deficiency (PID) in UK (2016-2028) 
Figure 26: Diagnosed Cases of the Primary Immune Deficiency (PID) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 29: Sex- Specific Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028) 
Figure 30: Diagnosed Cases of the Primary Immune Deficiency (PID) in Japan (2016-2028)

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.